190 related articles for article (PubMed ID: 30642983)
1. TCR Retrogenic Mice as a Model To Map Self-Tolerance Mechanisms to the Cancer Mucosa Antigen GUCY2C.
Abraham TS; Flickinger JC; Waldman SA; Snook AE
J Immunol; 2019 Feb; 202(4):1301-1310. PubMed ID: 30642983
[TBL] [Abstract][Full Text] [Related]
2. Split tolerance permits safe Ad5-GUCY2C-PADRE vaccine-induced T-cell responses in colon cancer patients.
Snook AE; Baybutt TR; Xiang B; Abraham TS; Flickinger JC; Hyslop T; Zhan T; Kraft WK; Sato T; Waldman SA
J Immunother Cancer; 2019 Apr; 7(1):104. PubMed ID: 31010434
[TBL] [Abstract][Full Text] [Related]
3. Human GUCY2C-Targeted Chimeric Antigen Receptor (CAR)-Expressing T Cells Eliminate Colorectal Cancer Metastases.
Magee MS; Abraham TS; Baybutt TR; Flickinger JC; Ridge NA; Marszalowicz GP; Prajapati P; Hersperger AR; Waldman SA; Snook AE
Cancer Immunol Res; 2018 May; 6(5):509-516. PubMed ID: 29615399
[TBL] [Abstract][Full Text] [Related]
4. Selective antigen-specific CD4(+) T-cell, but not CD8(+) T- or B-cell, tolerance corrupts cancer immunotherapy.
Snook AE; Magee MS; Schulz S; Waldman SA
Eur J Immunol; 2014 Jul; 44(7):1956-66. PubMed ID: 24771148
[TBL] [Abstract][Full Text] [Related]
5. Epitope-targeted cytotoxic T cells mediate lineage-specific antitumor efficacy induced by the cancer mucosa antigen GUCY2C.
Snook AE; Magee MS; Marszalowicz GP; Schulz S; Waldman SA
Cancer Immunol Immunother; 2012 May; 61(5):713-23. PubMed ID: 22057677
[TBL] [Abstract][Full Text] [Related]
6. Prime-Boost Immunization Eliminates Metastatic Colorectal Cancer by Producing High-Avidity Effector CD8
Xiang B; Baybutt TR; Berman-Booty L; Magee MS; Waldman SA; Alexeev VY; Snook AE
J Immunol; 2017 May; 198(9):3507-3514. PubMed ID: 28341670
[TBL] [Abstract][Full Text] [Related]
7. Tumor radiation therapy creates therapeutic vaccine responses to the colorectal cancer antigen GUCY2C.
Witek M; Blomain ES; Magee MS; Xiang B; Waldman SA; Snook AE
Int J Radiat Oncol Biol Phys; 2014 Apr; 88(5):1188-95. PubMed ID: 24661671
[TBL] [Abstract][Full Text] [Related]
8. Retrogenic modeling of experimental allergic encephalomyelitis associates T cell frequency but not TCR functional affinity with pathogenicity.
Alli R; Nguyen P; Geiger TL
J Immunol; 2008 Jul; 181(1):136-45. PubMed ID: 18566378
[TBL] [Abstract][Full Text] [Related]
9. Preclinical Evaluation of a Replication-Deficient Recombinant Adenovirus Serotype 5 Vaccine Expressing Guanylate Cyclase C and the PADRE T-helper Epitope.
Snook AE; Baybutt TR; Hyslop T; Waldman SA
Hum Gene Ther Methods; 2016 Dec; 27(6):238-250. PubMed ID: 27903079
[TBL] [Abstract][Full Text] [Related]
10. TCR affinity and tolerance mechanisms converge to shape T cell diabetogenic potential.
Bettini M; Blanchfield L; Castellaw A; Zhang Q; Nakayama M; Smeltzer MP; Zhang H; Hogquist KA; Evavold BD; Vignali DA
J Immunol; 2014 Jul; 193(2):571-9. PubMed ID: 24943217
[TBL] [Abstract][Full Text] [Related]
11. A Novel GUCY2C-CD3 T-Cell Engaging Bispecific Construct (PF-07062119) for the Treatment of Gastrointestinal Cancers.
Mathur D; Root AR; Bugaj-Gaweda B; Bisulco S; Tan X; Fang W; Kearney JC; Lucas J; Guffroy M; Golas J; Rohde CM; Stevens C; Kamperschroer C; Kelleher K; Lawrence-Henderson RF; Upeslacis E; Yao J; Narula J; LaVallie ER; Fernandez DR; Buetow BS; Rosfjord E; Bloom L; King LE; Tchistiakova L; Nguyen A; Sapra P
Clin Cancer Res; 2020 May; 26(9):2188-2202. PubMed ID: 31996389
[TBL] [Abstract][Full Text] [Related]
12. GUCY2C-targeted cancer immunotherapy: past, present and future.
Snook AE; Magee MS; Waldman SA
Immunol Res; 2011 Dec; 51(2-3):161-9. PubMed ID: 22038530
[TBL] [Abstract][Full Text] [Related]
13. Chimeric Ad5.F35 vector evades anti-adenovirus serotype 5 neutralization opposing GUCY2C-targeted antitumor immunity.
Flickinger JC; Singh J; Carlson R; Leong E; Baybutt TR; Barton J; Caparosa E; Pattison A; Rappaport JA; Roh J; Zhan T; Bashir B; Waldman SA; Snook AE
J Immunother Cancer; 2020 Aug; 8(2):. PubMed ID: 32819976
[TBL] [Abstract][Full Text] [Related]
14. Impact of effector cell differentiation on CD4+ T cells that evade negative selection by a self-peptide.
Boesteanu A; Rankin AL; Caton AJ
Int Immunol; 2006 Jul; 18(7):1017-27. PubMed ID: 16702167
[TBL] [Abstract][Full Text] [Related]
15. CD8 T cell tolerance to a tumor-associated self-antigen is reversed by CD4 T cells engineered to express the same T cell receptor.
Ghorashian S; Veliça P; Chua I; McNicol AM; Carpenter B; Holler A; Nicholson E; Ahmadi M; Zech M; Xue SA; Uckert W; Morris E; Chakraverty R; Stauss HJ
J Immunol; 2015 Feb; 194(3):1080-9. PubMed ID: 25539815
[TBL] [Abstract][Full Text] [Related]
16. GUCY2C-directed CAR-T cells oppose colorectal cancer metastases without autoimmunity.
Magee MS; Kraft CL; Abraham TS; Baybutt TR; Marszalowicz GP; Li P; Waldman SA; Snook AE
Oncoimmunology; 2016; 5(10):e1227897. PubMed ID: 27853651
[TBL] [Abstract][Full Text] [Related]
17. Rapid analysis of T-cell selection in vivo using T cell-receptor retrogenic mice.
Holst J; Vignali KM; Burton AR; Vignali DA
Nat Methods; 2006 Mar; 3(3):191-7. PubMed ID: 16489336
[TBL] [Abstract][Full Text] [Related]
18. Effective NY-ESO-1-specific MHC II-restricted T cell receptors from antigen-negative hosts enhance tumor regression.
Poncette L; Chen X; Lorenz FK; Blankenstein T
J Clin Invest; 2019 Jan; 129(1):324-335. PubMed ID: 30530988
[TBL] [Abstract][Full Text] [Related]
19. Intestinal GUCY2C prevents TGF-β secretion coordinating desmoplasia and hyperproliferation in colorectal cancer.
Gibbons AV; Lin JE; Kim GW; Marszalowicz GP; Li P; Stoecker BA; Blomain ES; Rattan S; Snook AE; Schulz S; Waldman SA
Cancer Res; 2013 Nov; 73(22):6654-66. PubMed ID: 24085786
[TBL] [Abstract][Full Text] [Related]
20. Sublingual tolerance induction with antigen conjugated to cholera toxin B subunit induces Foxp3+CD25+CD4+ regulatory T cells and suppresses delayed-type hypersensitivity reactions.
Sun JB; Cuburu N; Blomquist M; Li BL; Czerkinsky C; Holmgren J
Scand J Immunol; 2006 Sep; 64(3):251-9. PubMed ID: 16918694
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
